Follow
Mohd Feroz Mohd Omar Morris
Mohd Feroz Mohd Omar Morris
Hematogenix Laboratory Services, LLC
Verified email at u.nus.edu
Title
Cited by
Cited by
Year
The Warburg effect and drug resistance
B Bhattacharya, MF Mohd Omar, R Soong
British journal of pharmacology 173 (6), 970-979, 2016
2592016
Methodological aspects of whole-genome bisulfite sequencing analysis
S Adusumalli, MF Mohd Omar, R Soong, T Benoukraf
Briefings in bioinformatics 16 (3), 369-379, 2015
962015
Significance of immune checkpoint proteins in EGFR-mutant non-small cell lung cancer
RA Soo, HR Kim, BR Asuncion, Z Fazreen, MFM Omar, MC Herrera, ...
Lung Cancer 105, 17-22, 2017
562017
Characterization of Numb expression in astrocytomas
B Yan, FM Omar, K Das, WH Ng, C Lim, K Shiuan, CT Yap, M Salto‐Tellez
Neuropathology 28 (5), 479-484, 2008
512008
Cofilin immunolabelling correlates with depth of invasion in gastrointestinal endocrine cell tumors
B Yan, CT Yap, S Wang, CK Lee, S Koh, MF Omar, M Salto-Tellez, ...
Acta histochemica 112 (1), 101-106, 2010
332010
TRARESA: a tissue microarray-based hospital system for biomarker validation and discovery
K Das, MF Mohd Omar, CW Ong, S Bin Abdul Rashid, BK Peh, TC Putti, ...
Pathology 40 (5), 441-449, 2008
262008
Determinants of variability of five programmed death ligand-1 immunohistochemistry assays in non-small cell lung cancer samples
RA Soo, JSY Lim, BR Asuncion, Z Fazreen, MC Herrera, MFM Omar, ...
Oncotarget 9 (6), 6841, 2018
232018
Acquired resistance to PI3K/mTOR inhibition is associated with mitochondrial DNA mutation and glycolysis
KX Koh, GH Tan, SHH Low, MFM Omar, MJ Han, B Iacopetta, R Soo, ...
Oncotarget 8 (66), 110133, 2017
212017
RUNX3 Downregulation in Human Lung Adenocarcinoma is Independent of p53, EGFR or KRAS Status
MFM Omar, K Ito, ME Nga, R Soo, BK Peh, TM Ismail, B Thakkar, R Soong, ...
Pathology & Oncology Research 18, 783-792, 2012
142012
Lack of RUNX3 inactivation in columnar cell lesions of breast
MM Subramaniam, JY Chan, MFM Omar, K Ito, Y Ito, KG Yeoh, ...
Histopathology 57 (4), 555-563, 2010
122010
Molecular-assisted immunohistochemical optimization
MFM Omar, N Huang, K Ou, K Yu, TC Putti, H Jikuya, T Ichikawa, ...
Acta histochemica 112 (6), 519-528, 2010
112010
P2. 01-058 Mutational features associated with immunoreactivity in non-small cell lung cancer: topic: immune mechanisms in thoracic cancer and targeted therapy
N Syn, D Tay, MFM Omar, JX Teo, J Lim, R Soo, R Soong
Journal of Thoracic Oncology 12 (1), S821, 2017
72017
Effect of cell microenvironment on the drug sensitivity of hepatocellular cancer cells
B Bhattacharya, DQ Huang, SHH Low, GH Tan, MJ Han, S Singh, B Tang, ...
Oncotarget 12 (7), 674, 2021
42021
Whole exome sequencing of multi-regional biopsies from metastatic lesions to evaluate actionable truncal mutations using a single-pass percutaneous technique
V Heong, D Tay, SE Goh, B Wee, TZ Tan, R Soo, B Pang, D Lim, ...
Cancers 12 (6), 1599, 2020
32020
P3-010: Using immunohistochemistry to evaluate protein expression levels of female sex hormone receptors (ER, PR) and epidermal growth factor receptor family members (EGFR …
ME Nga, MFM Omar, DG Lim, D Lim, CK Toh, R Soong, MS Tellez, ...
Journal of Thoracic Oncology 2 (8), S502-S503, 2007
22007
Precision oncology: mind the disruption
R Soong, N Syn, K Wang, MFM Omar
Biochemist 38 (1), 14-18, 2016
12016
A novel in vitro microenvironment modeling platform for HCC therapeutics and biomarker development
MFM Omar, B Tang, SC Chang, SHH Low, GH Tan, R Soong, ...
Cancer Research 77 (13_Supplement), 165-165, 2017
2017
Abstract B52: Bioenergetic switch confers acquired resistance to BEZ235 in EGFR T790M-mutant non-small cell lung cancer
B Bhattacharya, KX Koh, MF Mohamed Omar, S Low, J Tan, NS Sapari, ...
Molecular Cancer Therapeutics 14 (12_Supplement_2), B52-B52, 2015
2015
Programmed death ligand-1 (PDL1) and CD3 co-expression in patients with advanced stage EGFR mutant NSCLC treated with EGFR tyrosine kinase inhibitors (TKI)
RA Soo, HR Kim, BR Asuncion, Z Fazreen, MFM Omar, MC Herrera, ...
Annals of Oncology 26, viii5, 2015
2015
PD-L1 Expression in Tumor Infiltrating Immune Cells Determined by Digital Imaging Is Associated with Poor Survival in NSCLC Patients
BGR Asuncion, Z Fazreen, MFM Omar, NLM Salleh, MA Rozario, ME Nga, ...
JOURNAL OF THORACIC ONCOLOGY 10 (9), S600-S600, 2015
2015
The system can't perform the operation now. Try again later.
Articles 1–20